BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Sells $54,880.00 in Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.86, for a total transaction of $54,880.00. Following the completion of the transaction, the director now owns 564,754 shares of the company’s stock, valued at $3,874,212.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of NASDAQ:BDSI traded down $0.06 during trading on Wednesday, reaching $6.70. The stock had a trading volume of 1,116,894 shares, compared to its average volume of 974,221. The firm’s fifty day moving average is $5.91 and its 200 day moving average is $4.74. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.02 and a current ratio of 2.25. BioDelivery Sciences International, Inc. has a 52 week low of $2.80 and a 52 week high of $7.01. The stock has a market cap of $605.16 million, a price-to-earnings ratio of -9.18 and a beta of 0.49.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.34. BioDelivery Sciences International had a negative net margin of 22.11% and a negative return on equity of 8.80%. The company had revenue of $30.31 million for the quarter, compared to analyst estimates of $28.86 million. On average, research analysts forecast that BioDelivery Sciences International, Inc. will post 0.02 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of BioDelivery Sciences International by 277.2% in the 2nd quarter. BlackRock Inc. now owns 5,498,457 shares of the specialty pharmaceutical company’s stock valued at $25,568,000 after purchasing an additional 4,040,621 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of BioDelivery Sciences International by 30.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,395,428 shares of the specialty pharmaceutical company’s stock valued at $15,788,000 after purchasing an additional 793,179 shares during the last quarter. Stonepine Capital Management LLC boosted its stake in shares of BioDelivery Sciences International by 79.6% in the 2nd quarter. Stonepine Capital Management LLC now owns 2,764,475 shares of the specialty pharmaceutical company’s stock valued at $12,855,000 after purchasing an additional 1,225,038 shares during the last quarter. Emerald Advisers LLC boosted its stake in shares of BioDelivery Sciences International by 11.4% in the 3rd quarter. Emerald Advisers LLC now owns 2,084,685 shares of the specialty pharmaceutical company’s stock valued at $8,777,000 after purchasing an additional 212,553 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust boosted its stake in shares of BioDelivery Sciences International by 13.8% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,944,531 shares of the specialty pharmaceutical company’s stock valued at $8,186,000 after purchasing an additional 236,254 shares during the last quarter. 69.44% of the stock is currently owned by institutional investors.

Several brokerages have issued reports on BDSI. ValuEngine upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub upgraded shares of BioDelivery Sciences International from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 16th. Janney Montgomery Scott restated a “buy” rating on shares of BioDelivery Sciences International in a research report on Wednesday, November 13th. William Blair restated a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. Finally, LADENBURG THALM/SH SH upped their price target on shares of BioDelivery Sciences International from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $6.50.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: What is the definition of a trade war?

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.